TENT/Docket No.: 6322.N Serial No.: 10/076,708

Page No. 1

CERTIFICATE OF MAILING (37 CFR 1.8)

Date of Deposit with U.S. Postal Service: _

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail under 37 CFR 1.8 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington D.C. 20231.

Julie K. Lyons, Legal Assistant

Name of Person Mailing Paper

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

1641

Examiner

Unknown

RECEIVED

Applicant(s)

SK Sharma, KB Rank

FEB **n 5** 2003

Serial No.

10/076,708

TECH CENTER 1600/2900

Filed

02/15/2002

For

ASSAYS FOR ASSESSING Aβ-TAU AGGREGATION

Commissioner of Patents and Trademarks Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL **UNDER 37 CFR 1.97 AND 1.98**

Sir:

Information Disclosed. The information disclosed consists of the following:

[X]	form PL-1449,	Provided herewith	are copies of patent(s)	and/or publication(s) as	listed in the
a	ttached form PL	1449.	• • • • • • • • • • • • • • • • • • • •	1	

IJ	At least to the extent required under §1.98(a)(3), a concise explanation of the relevance
	of references listed in form PL-1449 is:

[]	contained in the above-captioned specification as filed;
[]	provided in a communication enclosed with this paper;

[] provided in the International Search Report enclosed with this paper; and/or

[] not necessary as all of the references cited are in the English language.

Form 97.1 (short) 5/27/99

<u>PATENT</u>/Docket No.: 6322.N Serial No.: 10/076,708

Page No. 2

[] Disclosure from Predecessor Application. Provided herewith is a copy (or the copy is already present in the present file wrapper in accordance with §1.53(d)) of one or more forms PL-1449 and/or search/examination reports of record in this or a predecessor application, Serial No. filed , the benefit of which is claimed under 35 USC 120. Copies of references are present in the prosecution history of the referenced application and are not supplied herewith pursuant to §1.98(d).

Basis for Consideration. This information disclosure statement is entitled to consideration by the Office under:

- [] §1.97(b), as being filed within three months of the filing date of the above-captioned application and/or the date of entry of the National Stage, if later, and/or before the mailing date of the first Office action on the merits. Applicant(s) is/are unaware that any office action has issued in this case. However, in the event a first office action has issued, prior to the mailing of this document, then authorization is given to charge the late fee to the deposit account identified below.
- [X] §1.97(c), as being filed after the period specified in §1.97(b), but before the mailing date of a final action under §1.113 and/or the notice of allowance under §1.311.

 Consideration of this information disclosure statement at this time is requested for the reason checked below:
 - [X] Authorization is hereby provided to charge Deposit Account No. 21-0718 the fee set forth in §1.17(p), \$240.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.
 - A statement as specified in 37 CFR 1.97(e) below.
- [] $\S1.97(d)$, as being filed after the period specified in $\S1.97(c)$, but on or before payment of the issue fee and is accompanied by:
 - [] Authorization to charge Deposit Account No. 21-0718 the fee set forth in \$1.17(i), \$130.00, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.
 - [] A petition requesting consideration of the information disclosure statement; and
 - [] A statement as specified in 37 CFR 1.97 (e) below.
- [] §1.97(e), this is a supplemental information disclosure statement. A prior information disclosure statement has already been filed. Applicant certifies, as provided in 37 CFR 1.97 (e), that

<u>PATENT</u>/Docket No.: 6322.N Serial No.: 10/076,708

Page No. 3

[] Each new item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

[] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing below, after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three (3) months prior to the filing of this statement.

Disclaimer. In accordance with §1.97(g) and (h), the filing of this information disclosure statement is not to be construed as an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56, and is not to be construed as a representation that a search has been made.

Respectfully submitted,

Edward F. Rehberg, Attorney

Registration No. 34,703

Pharmacia & Upjohn Company Global Intellectual Property 301 Henrietta Street Kalamazoo, Michigan 49001

Telephone No. (269) 833-7829 or (269) 833-9500 Telefax No. (269) 833-8897 or (269) 833-2316

Attachment(s)

- [X] Form 1449 with copies of reference(s)
- [] Form 1449 from predecessor application (no references)
- [] Communication providing concise explanation of relevance
- [] International Search Report

			Atty. Docket No.			Serial No. 10/076,708			
THE D		ERENCES CITE	ED BY APPLICANT		6322.N			0,010,100	
E FEB. 0	•	2 \		Applicant SK Sharma, KB Rank					
FEB. 0	ع يدد			Filing Date 02/15/2002		Group 1641			
TRA	DEMARCE		U.S. PA	ATENT DOCUM	ENTS		<u>. </u>		
Examiner Initial		Document Number	Date	Name		Class	Subclass	Filing Da	
	AA								
	AB								
	AC			199-201-0-10-10-1					-
	AD						RE	ECEI	1FD
	AE							-D 0 5	2003 R 1600/2900
	AF			J				ED 11	
	AG						TECH	CENTE	7 1600 200
	AH						•		
	AI								
			FOREIGN	PATENT DOCU	JMENTS				
		Document Number	Date	Country		Class	ss Subclass Transla		ion
	_							Yes	No
	AJ								
,	AK								
	AL								
	AM								
	AN								
			OTHER PRIOR ART (Inc	cluding Author, Title,	Date, Pertinent P	Pages, Etc.)			
	AO	Bancher, C. et al., "Accumulation of abnormally phosphorylated \(\tau\) precedes the formation of neurofibrillary tangles in Alzheimer's disease," Brain Research 477(1-2):90-99 [1989];							
	AP	Bondareff, W. et al., "Molecular analysis of neurofibrillary degeneration in Alzheimer's Disease," American J. of Pathology 137(3):711-23 [1990];							
	AQ	Caceres, A. et al., "Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons," Nature 343(6257):461-63 [1990];							
	AR	Drubin, D.G. et	al., "Tau protein function	n in living cells,"	J. Cell Biology	103(6 P	ſ 2):2739-46	[1986];	
	AS	Evans, D.B. et al., "Tau phosphorylation at Serine 396 and Serine 404 by human recombinant Tau protein kinase II inhibits Tau's ability to promote microtubule assembly," J. Biological Chemistry 275(32):24977-983 [2000];							
	AT	Glenner, G.G. e cerebrovascular	t al., "Alzheimer's Diseas amyloid protein," Bioche	se: Initial report o	of the purificat sysical Researc	ion and c	haracterizat unications 1	ion of a no 20(3):885-9	vel 90

		_	Atty.	Docket No.	Serial No.			
				6322.N	10/076,708			
STP.		ERENCES CITED BY APPLICANT Use several sheets if necessary)			RECEIVED			
	161		Applicant	SK Sharma, KB Rar	nk 5 2003			
FEB. 0 3 20	O I		Filing Date	02/15/2002	Group FEB A 5 2003 TECH CENTER 1600			
PANEMAR		[1984];	1		TECH CENTER TO			
THE SIC	AV	Goedert, M. et al., "Cloning and sequenc of Alzheimer disease: Identification as the			of the paired helical filament			
	AW	Goedert, M. et al., "Multiple isoforms of in neurofibrillary tangles of Alzheimer's			au: Sequences and localization			
	AX		osion of separate isoforms of human tau protein: correlation with the tau pattern in in polymerization," The EMBO Journal 9(13): 4225-30 [1990];					
	AY	Goedert, Michael, "Tau protein and the Reuroscience 16(11):460-65 [1993];	neurofibrillary p	athology of Alzheimer's	Disease," Trends in			
	AZ	Greenberg, S.G., et al., "A preparation of Alzheimer paired helical filaments that displays distinct τ proteins by polyacrylamide gel electrophoresis," PNAS 87(15):5827-31 [1990];						
	во	Himmler, Adolf, "Structure of the bovine Molecular and Cellular Biology 9(4):138		natively spliced transcri	pts generate a protein family,"			
	ВР	Horio, T. et al., "Visualization of the dyn Nature 321(6070):605-7 [1986];	amic instability	of individual microtubu	les by dark-field microscopy,"			
	BQ	Kosik, K.S., "Tau protein and Alzheimer	's disease," Curr	ent Opinion in Cell Biol	ogy 2(1):101-4 [1990];			
	BR	Kosik, K.S., "Alzheimer plaques and tan	gles: advances o	n both fronts," TINS 14(6):218-19 [1991];			
	BS	Kosik, K.S. et al., "Microtubule-associate filaments in Alzheimer disease," PNAS			mponent of paired helical			
	вт	Ksiezak-Reding et al., "Structural stabiliof tau: A model for self-association," Neu			icrotubule-binding domains			
	BU	Lee, G. et al., "The primary structure an 239(4837):285-88 [1988];	d heterogeneity	of tau protein from mou	se brain," Science			
	BV	Lee, V.MY., et al., "A68: A major subun Science 251(4994):675-78 [1991];	l., "A68: A major subunit of paired helical filaments and derivatized forms of normal tau," 0:675-78 [1991];					
	BW	Lee, V.MY., et al., "The disordered neuronal cytoskeleton in Alzheimer's disease," Current Opinion in Neurobiology 2(5):653-56 [1992];						
	вх	Mailliot, C. et al., "Phosphorylation of sp degeneration processes," FEBS Letters 4			nt neurofibrillary			
	BY	Spillantini, M.G. et al., "Tau protein pat 21(10):428-33 [1998];	hology in neurod	legenerative diseases," T	rends in Neuroscience			
	BZ	Weingarten, M.D. et al., "A protein facto	r essential for m	icrotubule assembly," P	NAS 72(5):1858-62 [1975].			
	СО		····					
	СР							
Examiner			Date Consider	ed				